Condition
Diabetes Mellitus, Type 1
Locations
Germany
Start date
15/12/2025
Identifiers
Trial ID NN1644-8194,
NCT number NCT07305805,
Eudract number Not Available
NCT number NCT07305805,
Eudract number Not Available
Summary
The purpose of this clinical study is to find out how the novel insulin NNC0363-1063 and a non-glucose carbohydrate used in food and beverage might interact in participants with type 1 diabetes and if co-administration of these substances is safe and tolerable. All participants will get a fixed dose of NNC0363-1063 and an oral administration of different amounts of the non-glucose carbohydrate in a random order during 4 interaction tests. The participants will be in this clinical study for about 5 to 12 weeks.
Trial Overview:
Treatment
DRUG: NNC0363-1063
Study type
INTERVENTIONAL
Trial duration
Dec 15 2025 - May 21 2026
Participants
36
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 64 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.